LUYE PHARMA News

LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

Apr 8 05:16 ET

LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLED FOR PHASE 3 CLINICAL STUDY OF THE GROUP''S INNOVATIVE FORMULATION LY01610

Mar 4 07:30 ET

LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

Mar 1 03:38 ET

LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - UPDATED PROGRESS IN RELATION TO THE MARKETING REVIEW OF PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION (LY03010) IN THE UNITED STATES

Feb 1 09:30 ET

LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024

Feb 1 03:44 ET

LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING IN THE COMPANY BY CONTROLLING SHAREHOLDER

Jan 12 08:00 ET

LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023

Jan 3 03:40 ET

LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - INNOVATIVE FORMULATIONS BAITUOWEI AND RYKINDO INCLUDED ON CHINA''S 2023 NATIONAL REIMBURSEMENT DRUG LIST

Dec 12, 2023 23:02 ET

LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - INNOVATIVE DRUG LURBINECTEDIN APPROVED FOR MARKETING IN HONG KONG

Dec 12, 2023 07:30 ET

LUYE PHARMA: LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION

Dec 6, 2023 09:01 ET

LUYE PHARMA: CHANGE OF NON-EXECUTIVE DIRECTOR

Dec 6, 2023 09:00 ET

LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - INNOVATIVE DRUG LURBINECTEDIN APPROVED FOR THE TREATMENT OF RELAPSED SMALL CELL LUNG CANCER IN MACAO, CHINA

Dec 3, 2023 23:03 ET

LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023

Dec 1, 2023 04:08 ET

LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023

Nov 3, 2023 07:39 ET

LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - RIVASTIGMINE TWICE WEEKLY TRANSDERMAL PATCH APPROVED FOR MARKETING IN CHINA

Oct 31, 2023 06:21 ET

LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - THE COMPANY SUBMITTED NDA FOR PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION (LY03010) TO THE FDA

Oct 9, 2023 04:30 ET

LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023

Oct 6, 2023 04:40 ET

LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - THE BREAST CANCER INDICATION OF BAITUOWEI (GOSERELIN MICROSPHERES FOR INJECTION) APPROVED IN CHINA

Sep 7, 2023 07:00 ET

LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023

Sep 4, 2023 08:55 ET

LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - SUBMISSION OF NEW DRUG APPLICATION FOR LURBINECTEDIN BY THE GROUP IN MACAO, CHINA

Aug 21, 2023 09:00 ET